179 related articles for article (PubMed ID: 17031283)
1. Avastin and new treatments for AMD: where are we?
Freeman WR; Falkenstein I
Retina; 2006 Oct; 26(8):853-8. PubMed ID: 17031283
[No Abstract] [Full Text] [Related]
2. Intravitreal avastin: the low cost alternative to lucentis?
Rosenfeld PJ
Am J Ophthalmol; 2006 Jul; 142(1):141-3. PubMed ID: 16815262
[No Abstract] [Full Text] [Related]
3. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ziemssen F; Heiduschka P; Schraermeyer U;
Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
[No Abstract] [Full Text] [Related]
4. Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.
Klein RM; Klein RB
Retina; 2007; 27(9):1163-5. PubMed ID: 18046218
[No Abstract] [Full Text] [Related]
5. Avastin versus Lucentis: ethical issues.
Wong HC
Retina; 2008; 28(7):1024-5; author reply 1025. PubMed ID: 18698312
[No Abstract] [Full Text] [Related]
6. Bevacizumab: a new way of doing business?
Canning C; Lotery A
Eye (Lond); 2006 Sep; 20(9):985-7. PubMed ID: 16858443
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
Bom Aggio F; Eid Farah M; Melo GB
Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
[No Abstract] [Full Text] [Related]
8. Comparing ranibizumab with bevacizumab.
Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
[No Abstract] [Full Text] [Related]
9. Intravitreal bevacizumab.
Lucas RS; McKee HD; Lee LR
Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
[No Abstract] [Full Text] [Related]
10. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?
la Cour M
Acta Ophthalmol Scand; 2007 Feb; 85(1):2-4. PubMed ID: 17244202
[No Abstract] [Full Text] [Related]
11. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Spandau UH; Jonas JB
Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
[No Abstract] [Full Text] [Related]
13. Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
Schmucker C; Antes G; Lelgemann M
Surv Ophthalmol; 2009; 54(6):705-7. PubMed ID: 19818262
[No Abstract] [Full Text] [Related]
14. Sixth nerve palsy post intravitreal bevacizumab for AMD: a new possibly causal relationship and complication?
Park HJ; Guy J
Binocul Vis Strabismus Q; 2007; 22(4):209. PubMed ID: 18163895
[No Abstract] [Full Text] [Related]
15. Controversies in the treatment of wet age-related macular degeneration.
Moreno SF; Paloma JB
Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
[No Abstract] [Full Text] [Related]
16. Antiangiogenic therapy in neovascular age-related macular degeneration.
Lin RC; Rosenfeld PJ
Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
[No Abstract] [Full Text] [Related]
17. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
Retina; 2006; 26(9):994-8. PubMed ID: 17151485
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
Jonas JB; Tao Y; Rensch F
Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
[No Abstract] [Full Text] [Related]
19. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
El-Mollayess GM; Noureddine BN; Bashshur ZF
Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
[TBL] [Abstract][Full Text] [Related]
20. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system.
Spaide RF
Am J Ophthalmol; 2009 Jul; 148(1):1-3. PubMed ID: 19540983
[No Abstract] [Full Text] [Related]
[Next] [New Search]
